DRKS00008183
Completed
Not Applicable
on-interventional study to evaluate neurotoxicity under therapy with Docetaxel Omnicare for patients with various tumor entities - NORDIC
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- C50
- Sponsor
- OMNICARE Pharma GmbH
- Enrollment
- 109
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Male and female patients \= 18 years
- •2\. Diagnosis of tumor disease for which a chemotherapy with Docetaxel Omnicare is indicated
- •3\. Investigator's decision (independent of study participation) to treat the patient with Docetaxel Omnicare®
- •4\. Sufficient patient's compliance upon investigator's assessment
- •5\. Written informed consent of the patient to retrospective and prospective pseudonomized documentation, to forwarding and analysis of the data and to access to the data within monitoring
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Klinische Studie zur Überprüfung der Auswirkungen einer präoperativen Verabreichung von Glutamin und/oder Omega-3-Fettsäuren auf das Inflammationsgeschehen nach aortokoronaren Bypassoperationen - Inflammation-Bypassoperation-StudieIndikationsstellung für eine aortokoronare BypassoperationEUCTR2008-003971-30-ATniv.-Prof. Dr. Karlheinz Tscheliessnigg
Completed
Phase 3
A clinical trial to study the effect of two different radiotherapy treatment techniques in patients with cancer cervixHealth Condition 1: null- CARCINOMA CERVIXCTRI/2018/05/014021POST GRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH80
Not yet recruiting
Phase 3
A Prospective randomized study to compare haematological toxicities and response between two different chemotherapy regimens in chemoradiotherapy treatment of carcinoma of uterine cervix.CTRI/2024/08/072198SRI VENKATESHWARA INSTITUTE OF MEDICAL SCIENCES
Active, not recruiting
Phase 1
The evaluation of safety and biological effects of cancer-killing virus vaccine given to patients with advanced brain tumoursMalignant neoplasm of brain, high-grade brain tumourCancerMalignant neoplasm of brainISRCTN51762486niversity of Leeds12
Active, not recruiting
Phase 1
A clinical study to evaluate the effect of rimantadine in patients with hepatitis C virus (HCV) infection alongside standard treatment with pegylated interferon and ribavirin.EUCTR2011-002781-21-GBeeds Teaching Hospitals22